Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Debiopharm International SA
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic HCV genotype 1 viral infection
HCV RNA ≥ 1,000 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent at screening
Previous non-responders/relapsers to PEG and RBV after treatment for at least 12 weeks
You may not be if
Treatment with any anti-HCV drug (whether approved or investigational) within 3 months prior to screening
Women of child-bearing potential unless using highly effective
Any other cause of relevant liver disease other than HCV
Clareo Health | Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
